{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:07:20Z","timestamp":1783116440732,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12026-022-09312-w","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T15:03:29Z","timestamp":1665587009000},"page":"817-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-6085","authenticated-orcid":false,"given":"Yuval","family":"Volfovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avishai M.","family":"Tsur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gurevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilda","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Achiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menachem","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"9312_CR1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. 2022. https:\/\/covid19.who.int\/."},{"key":"9312_CR2","doi-asserted-by":"crossref","unstructured":"Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395:1033\u20134.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"9312_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ajh.25829","volume":"95","author":"E Terpos","year":"2020","unstructured":"Terpos E, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834\u201347.","journal-title":"Am J Hematol"},{"key":"9312_CR4","unstructured":"Dahan, S. et al. Ferritin as a marker of severity in COVID-19 patients: a fatal correlation. Isr Med Assoc J 22 429\u2013434 Preprint at (2020)."},{"key":"9312_CR5","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","volume":"11","author":"D Ragab","year":"2020","unstructured":"Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.","journal-title":"Front Immunol"},{"key":"9312_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250\u20136.","journal-title":"J Med Virol"},{"key":"9312_CR7","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255\u201373.","journal-title":"N Engl J Med"},{"key":"9312_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaci.2020.09.016","volume":"146","author":"SW Canna","year":"2020","unstructured":"Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146:949\u201359.","journal-title":"J Allergy Clin Immunol"},{"key":"9312_CR9","doi-asserted-by":"publisher","unstructured":"Rodrigues TS, de S\u00e1 KSG, Ishimoto AY,\u00a0et al. Inflammasomes are activated in response to SARS-cov-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2020;218(3):e20201707. https:\/\/doi.org\/10.1084\/jem.20201707","DOI":"10.1084\/jem.20201707"},{"key":"9312_CR10","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.4049\/jimmunol.2001327","volume":"206","author":"W Huang","year":"2021","unstructured":"Huang W, et al. The inflammatory factors associated with disease severity to predict COVID-19 progression. J Immunol. 2021;206:1597\u2013608.","journal-title":"J Immunol"},{"key":"9312_CR11","doi-asserted-by":"publisher","unstructured":"Perricone, C. et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020;68 213\u2013224 Preprint at https:\/\/doi.org\/10.1007\/s12026-020-09145-5.","DOI":"10.1007\/s12026-020-09145-5"},{"key":"9312_CR12","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/annrheumdis-2020-218048","volume":"79","author":"P Ruscitti","year":"2020","unstructured":"Ruscitti P, et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. Ann Rheum Dis. 2020;79:1152\u20135.","journal-title":"Ann Rheum Dis"},{"key":"9312_CR13","doi-asserted-by":"crossref","unstructured":"Ruscitti, P. et al. Severe COVID-19, Another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol. 2020;11:1\u20136.","DOI":"10.3389\/fimmu.2020.01130"},{"key":"9312_CR14","first-page":"1","volume":"2019","author":"BE Young","year":"2020","unstructured":"Young BE, et al. Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity. Clin Infect Dis. 2020;2019:1\u201311.","journal-title":"Clin Infect Dis"},{"key":"9312_CR15","doi-asserted-by":"publisher","first-page":"e0144","DOI":"10.1097\/CCE.0000000000000144","volume":"2","author":"DD Fraser","year":"2020","unstructured":"Fraser DD, et al. Inflammation profiling of critically ill coronavirus disease 2019 patients. Crit Care Explor. 2020;2:e0144.","journal-title":"Crit Care Explor"},{"key":"9312_CR16","doi-asserted-by":"publisher","unstructured":"Colafrancesco S, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60(2-3):177\u201383. https:\/\/doi.org\/10.1007\/s12026-014-8563-7.","DOI":"10.1007\/s12026-014-8563-7"},{"key":"9312_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.smim.2013.10.014","volume":"25","author":"D Novick","year":"2013","unstructured":"Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25:439\u201348.","journal-title":"Semin Immunol"},{"key":"9312_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","volume":"15","author":"CA Dinarello","year":"2019","unstructured":"Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15:612\u201332.","journal-title":"Nat Rev Rheumatol"},{"key":"9312_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1164\/rccm.201201-0003OC","volume":"185","author":"T Dolinay","year":"2012","unstructured":"Dolinay T, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012;185:1225\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"9312_CR20","doi-asserted-by":"publisher","first-page":"155302","DOI":"10.1016\/j.cyto.2020.155302","volume":"137","author":"H Sat\u0131\u015f","year":"2021","unstructured":"Sat\u0131\u015f H, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302.","journal-title":"Cytokine"},{"key":"9312_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1006\/bbrc.1999.0294","volume":"256","author":"A Droste","year":"1999","unstructured":"Droste A, Sorg C, H\u00f6gger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun. 1999;256:110\u20133.","journal-title":"Biochem Biophys Res Commun"},{"key":"9312_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1189\/jlb.0410235","volume":"88","author":"A Etzerodt","year":"2010","unstructured":"Etzerodt A, Maniecki MB, M\u00f8ller K, M\u00f8ller HJ, Moestrup SK. Tumor necrosis factor \u03b1-converting enzyme (TACE\/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol. 2010;88:1201\u20135.","journal-title":"J Leukoc Biol"},{"key":"9312_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.1002128","volume":"13","author":"TL Weissgerber","year":"2015","unstructured":"Weissgerber TL, Milic NM, Winham SJ, Garovic VD. Beyond bar and line graphs: time for a new data presentation paradigm. PLoS Biol. 2015;13:1\u201310.","journal-title":"PLoS Biol"},{"key":"9312_CR24","doi-asserted-by":"publisher","unstructured":"Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, D\u2019Cruz DP, Shoenfeld, Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrowphic antiphospholipid syndrome. BMC Med. 2013;11:185. https:\/\/doi.org\/10.1186\/1741-7015-11-185.","DOI":"10.1186\/1741-7015-11-185"},{"key":"9312_CR25","doi-asserted-by":"publisher","unstructured":"Mahroum N, et al. Ferritin - from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778. https:\/\/doi.org\/10.1016\/j.jaut.2021.102778.","DOI":"10.1016\/j.jaut.2021.102778"},{"key":"9312_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","volume":"29","author":"KF Kernan","year":"2017","unstructured":"Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29:401\u20139.","journal-title":"Int Immunol"},{"key":"9312_CR27","unstructured":"Ros\u00e1rio C, Shoenfeld Y. The hyperferritinemic syndrome. Isr Med Assoc J. 16 664\u2013665 Preprint at (2014)."},{"key":"9312_CR28","doi-asserted-by":"publisher","unstructured":"Wawrocki S, Druszczynska M, Kowalewicz-Kulbat M, Rudnicka, W. Interleukin 18 (IL-18) as a target for immune intervention. Acta Biochim Pol. 63 59\u201363 Preprint at https:\/\/doi.org\/10.18388\/abp.2015_1153 (2016).","DOI":"10.18388\/abp.2015_1153"},{"key":"9312_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/jcp.30008","volume":"236","author":"A Vecchi\u00e9","year":"2021","unstructured":"Vecchi\u00e9 A, et al. IL-18 and infections: is there a role for targeted therapies? J Cell Physiol. 2021;236:1638\u201357.","journal-title":"J Cell Physiol"},{"key":"9312_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.569760","volume":"11","author":"G Canedo-Marroqu\u00edn","year":"2020","unstructured":"Canedo-Marroqu\u00edn G, et al. SARS-CoV-2: immune response elicited by infection and development of vaccines and treatments. Front Immunol. 2020;11:1\u201319.","journal-title":"Front Immunol"},{"key":"9312_CR31","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis. 2018;77:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"9312_CR32","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139:1698\u2013701.","journal-title":"J Allergy Clin Immunol"},{"key":"9312_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cyto.2018.05.017","volume":"110","author":"N Sakumura","year":"2018","unstructured":"Sakumura N, et al. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;110:459\u201365.","journal-title":"Cytokine"},{"key":"9312_CR34","doi-asserted-by":"publisher","unstructured":"Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;19(6):102538. https:\/\/doi.org\/10.1016\/j.autrev.2020.102538.","DOI":"10.1016\/j.autrev.2020.102538"},{"key":"9312_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.627548","volume":"12","author":"MA Zingaropoli","year":"2021","unstructured":"Zingaropoli MA, et al. Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro-inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia. Front Immunol. 2021;12:1\u201312.","journal-title":"Front Immunol"},{"key":"9312_CR36","doi-asserted-by":"publisher","unstructured":"Ruscitti P, et al. Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Sci Rep. 2020;10(1):12232. https:\/\/doi.org\/10.1038\/s41598-020-69031-w.","DOI":"10.1038\/s41598-020-69031-w"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09312-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:33:59Z","timestamp":1668393239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09312-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9312"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09312-w","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"6 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}